Grünenthal GmbH
Privately held: no public share price
Assets
(4 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | TRPV1 (transient receptor potential vanilloid 1) channelSmall molecule | Diabetic Peripheral Neuropathic Pain Diabetic Peripheral Neuropathy | |
Esomeprazole(Nexium) | Approved | H+/K+-ATPase (gastric proton pump)Small molecule | Helicobacter pylori Infection |
| Approved | Mu-opioid receptor and norepinephrine transporter (NET)Small molecule | Diabetic Peripheral Neuropathic PainNeuropathic Pain Diabetic Peripheral Neuropathy, Peripheral Neuropathic Pain | |
| Phase 3 | Mesenchymal precursor cells (MPCs)Cell therapy | Heart FailureChronic Low Back Pain |
Discontinued programmes (1)
Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
July 2027 (1)
What to watch
Regulatory and conference events
(4)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
No financial reports recorded.